ADDvise receives allocation decision worth EUR 1.25 million

ADDvise Group AB (publ)’s subsidiary Sonar Oy has received an allocation decision from the Kanta-Häme region worth EUR 1.25 million. The allocation decision pertains to the delivery of x-ray equipment to three hospitals in the region during 2024 and early 2025.

The allocation decision is subject to a customary appeals period.

For further information, please contact:

Rikard Akhtarzand, CEO

+46 (0) 76-525 90 71

rikard.akhtarzand@addvisegroup.se

Important information

This information is such that ADDvise Group AB (publ) is obliged to disclose pursuant to the EU Market Abuse Regulation. The information was released for public disclosure, through the agency of the contact persons above, on April 5, 2024 at 15:30 CEST.

About ADDvise

ADDvise is an international life science group. Operating a decentralised ownership model, we develop and acquire high quality companies within the business areas Lab and Healthcare. The Group comprises more than 20 companies and generates annual revenues of close to SEK 2 billion. ADDvise is listed on Nasdaq First North Premier Growth Market. Mangold Fondkommission AB, +46 8 503 015 50, CA@mangold.se, is the Company's Certified Adviser. Additional information is available at www.addvisegroup.com.